Brief: Erytech Pharma End-FY Cash and Cash Equivalents Down At EUR 33.7 Mln

Phaxiam Therapeutics SA

14/03/2022 07:21

March 14(Reuters) - Erytech Pharma SA  ERYP.PA :
    * REPORTED ON FRIDAY UPDATE FOR THE FOURTH QUARTER AND FULL
YEAR
2021
    * AS OF DECEMBER 31, 2021, CASH AND CASH EQUIVALENTS
TOTALING
€33.7 MILLION, VS €44.4 MILLION AS OF DECEMBER 31, 2020
    * BELIEVES CURRENT CASH POSITION, WITHOUT CONSIDERING FUTURE
PROCEEDS FROM POTENTIAL STRATEGIC OPTIONS, CAN FUND PLANNED
OPERATING EXPENSES AND CURRENT PROGRAMS WELL INTO Q3
    * PROGRESS TOWARDS SEEKING APPROVAL OF GRASPA®; BLA ALMOST
READY
TO SUBMIT PENDING FDA’S ACCEPTANCE TO FILE APPLICATION

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nNDL2hkj8W
 Further company coverage:  ERYP.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))